Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) dropped 7.5% on Wednesday . The stock traded as low as $15.74 and last traded at $15.85, with a volume of 132,076 shares traded. The stock had previously closed at $17.13.

SNDX has been the topic of several research reports. Zacks Investment Research upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 20th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $24.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Syndax Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $25.00.

The company has a 50-day moving average of $12.59 and a 200-day moving average of $13.15. The stock’s market capitalization is $263.53 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. On average, equities research analysts anticipate that Syndax Pharmaceuticals Inc. will post ($3.01) EPS for the current fiscal year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.